rheumatology
JIA

NSAIDs downgraded in new guidelines for juvenile arthritis


Initial NSAID monotherapy for polyarthritis in juvenile idiopathic arthritis (JIA) has been rejected in the most recent 2019 American College of Rheumatology / Arthritis Foundation guidelines. The guidelines differ from the earlier 2011 version in recognising ‘the established benefits of early initiation of DMARD treatment’. As a result, NSAIDs have been downgraded to adjunct therapy, ...

Already a member?

Enter your email to keep reading.


OR